Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama, a drug for psoriasis that it claims could be a game-changer in the ...

Dermavant's phase 3 trials of tapinarof – PSOARING 1 and 2 – showed that around 40% of patients responded to treatment with clear or almost clear skin at 12 weeks, compared to 6% of a placebo ...

Its analysts expect the new Dermavant acquisition and Nexplanon results to be among the key focuses on the Q3 earnings call, ...

The company’s most notable recent move was the acquisition of Dermavant, a dermatology-focused firm, which has expanded Organon’s portfolio in the U.S. market. This acquisition aligns with the company ...